ferinject®
ferric carboxymaltose

CSL Vifor

Summary of Dosing and Administration for Paediatric Patients aged 1 to 13 years[1]

Ferinject® is not recommended for use in children below 1 year of age.
Please refer to the SmPC for dosing considerations in adults and adolescents aged 14 years and above.

Click here for prescribing information or scan the QR code on the reverse.
Adverse event reporting can be found on the reverse.

For children and adolescents aged 1 to 13 years, the maximum weekly dose is 750 mg iron, equivalent to 15 mL of Ferinject® per week. If the total iron need is higher, then the administration of an additional dose should be a minimum of 7 days apart from the first dose.

IV infusion: a single dose must not exceed 750 mg iron

IV injection: a single dose must not exceed 750 mg iron (15 mL)

The individual total iron need for repletion using Ferinject® is determined based on the patient's body weight and haemoglobin (Hb) level. Two doses may be required to replenish the total iron need. In children aged 1 to 13 years, the maximum cumulative dose must therefore not exceed 1,500 mg iron (2 x 750 mg with an interval of 7 days).

Ferinject should only be administered when staff trained to evaluate and manage anaphylactic reactions is immediately available, in an environment where full resuscitation facilities can be assured.[1]

Determination of the total iron need in patients <35 kg body weight

For the maximum weekly dose for patients with body weight >35 kg, please refer to the SmPC.

Hb		Patient body weight
g/dL	**mmol/L**	**<35 kg**
<10	<6.2	30 mg/kg body weight
10 to <14	6.2 to <8.7	15 mg/kg body weight
≥14	≥8.7	15 mg/kg body weight

Ferinject® administration by IV infusion or IV injection based on dose

IV Infusion[1]

Dose	Dilution range*†	Minimum administration time
100 to 200 mg	1 to 50 mL	No time limit
>200 to 500 mg	1 to 100 mL	6 minutes
>500 to 750 mg‡	1 to 250 mL	15 minutes

*For stability reasons, dilution to concentrations less than 2 mg iron/mL are not permissible.
†Maximum amount of sterile 0.9% m/V sodium chloride solution.
‡750 mg maximum per week in patients aged 1 to 13 years.[1]

IV Injection[1]

Dose	Volume of Ferinject® required§	Administration time/rate
100 to 200 mg	2 to 4 mL	No time limit
>200 to 500 mg	>4 to 10 mL	100 mg/min
>500 to 750 mg‖	>10 to 15 mL	15 minutes

§Administer undiluted Ferinject® by the intravenous injection route.[1] No test dose requirement but caution warranted.[2]
‖750 mg maximum per week in patients aged 1 to 13 years.[1]

Ferinject® is not recommended for use in children aged 1 to 13 years with chronic kidney disease requiring haemodialysis.

Safety information: The safety profile of Ferinject® in children and adolescents aged 1 to 17 years is comparable with that of adults. The most serious adverse drug reaction with Ferinject® is anaphylactic reactions with a frequency of rare (≥1/10,000 to <1/1,000). The patient should be observed for adverse effects for at least 30 minutes following each Ferinject® administration.[1]
Please refer to the Ferinject® SmPC for complete tolerability information.

Ferinject® is indicated for the treatment of iron deficiency when:

- **oral iron preparations are ineffective**
- **oral iron preparations cannot be used**
- **there is a clinical need to deliver iron rapidly**

The diagnosis of iron deficiency must be based on laboratory tests.[1]

Scan or click the QR code to access UK prescribing information for Ferinject® (ferric carboxymaltose)



Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Vifor Pharma UK Ltd. Tel: +44 1276 853633. Email: MedicalInfo_UK@viforpharma.com

References: 1. Ferinject® Summary of Product Characteristics; 2. EMA. *Intravenous iron-containing medicinal products*. Available at: **https://www.ema.europa.eu/en/medicines/human/referrals/intravenous-iron-containing-medicinal-products**. (Accessed March 2025).

UK-FCM-2500086 March 2025

CSL Vifor